Hematology News

ASH launched a clinical trials network designed to accelerate development of novel therapies for patients with sickle cell disease.

The Bill and Melinda Gates Foundation awarded a $1.5 million grant to Boston Children’s Hospital to research and develop gene therapy treatment for sickle cell disease.

Sutimlimab appeared to be a safe and effective treatment for patients with cold agglutinin disease, according to results of a first-in-human clinical trial of the anti-C1s monoclonal antibody published in Blood.

The FDA today approved ravulizumab injection for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

SAN DIEGO — An iron-rich diet between blood donations may not be adequate to help ferritin levels recover and prevent iron deficiencies, particularly among female and teenage donors, according to a presentation at ASH Annual Meeting and Exposition.

Caplacizumab is a safe, well-tolerated treatment for patients with acquired thrombotic thrombocytopenic purpura, according to findings from an integrated analysis presented at the ASH Annual Meeting and Exposition.

Patients diagnosed with cancer of any kind have an approximately 40% higher risk for developing shingles than patients without cancer, researchers found.

In recent years, the prevalence of moderate anemia after hospitalization has increased while red blood cell transfusions have decreased, but morbidity, mortality and rehospitalization have not been adversely affected, according to findings published in Annals of Internal Medicine.

The FDA today approved romiplostim for treatment of certain pediatric patients with immune thrombocytopenia, according to a press release from the agency.

The rate of thrombotic events among patients treated with coagulation factor VIIa recombinant within its licensed indications continues to be low and has remained stable in postapproval surveillance, according to findings presented at the ASH Annual Meeting and Exposition.